Satellos Bioscience And 2 Other TSX Penny Stocks To Watch

As 2025 begins, the Canadian market reflects on a stellar year with the TSX gaining 18%, driven by strong economic growth and rising corporate profits. In this climate, investors are increasingly considering diverse opportunities, including penny stocks—an often overlooked yet intriguing segment of the market. While traditionally associated with high risk, these smaller or newer companies can offer unique growth potential when backed by robust financials and solid fundamentals.

Top 10 Penny Stocks In Canada

Name	Share Price	Market Cap	Financial Health Rating
Mandalay Resources (TSX:MND)	CA$4.00	CA$379.39M	★★★★★★
Pulse Seismic (TSX:PSD)	CA$2.35	CA$122.01M	★★★★★★
Silvercorp Metals (TSX:SVM)	CA$4.36	CA$961.62M	★★★★★★
PetroTal (TSX:TAL)	CA$0.63	CA$583.7M	★★★★★★
Findev (TSXV:FDI)	CA$0.50	CA$15.47M	★★★★★★
Foraco International (TSX:FAR)	CA$2.45	CA$241.16M	★★★★★☆
NamSys (TSXV:CTZ)	CA$1.20	CA$30.89M	★★★★★★
East West Petroleum (TSXV:EW)	CA$0.035	CA$3.62M	★★★★★★
Orezone Gold (TSX:ORE)	CA$0.65	CA$307.33M	★★★★★☆
Hemisphere Energy (TSXV:HME)	CA$1.87	CA$178.48M	★★★★★☆

Click here to see the full list of 945 stocks from our TSX Penny Stocks screener.

Let's review some notable picks from our screened stocks.

Satellos Bioscience (TSX:MSCL)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Satellos Bioscience Inc. is a biotechnology company focused on developing regenerative therapeutics for degenerative muscle diseases, primarily operating in Canada and Australia, with a market cap of CA$100.16 million.

Operations: Satellos Bioscience Inc. has not reported any revenue segments.

Market Cap: CA$100.16M

Satellos Bioscience Inc., a pre-revenue biotechnology firm, recently completed a CA$56.96 million follow-on equity offering, bolstering its cash reserves to support ongoing clinical trials. The company is advancing its Phase 1b trial for Duchenne muscular dystrophy (DMD), having successfully dosed the first participant without adverse effects. Despite having no debt and sufficient cash runway for over a year, Satellos faces challenges with volatile share prices and increasing losses. The recent appointment of Stephanie Brown to the board brings significant industry experience, potentially aiding in strategic development as the company navigates its unprofitable status.

• Click to explore a detailed breakdown of our findings in Satellos Bioscience's financial health report.
• Gain insights into Satellos Bioscience's outlook and expected performance with our report on the company's earnings estimates.

Azimut Exploration (TSXV:AZM)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Azimut Exploration Inc. is involved in the acquisition, exploration, and evaluation of mineral properties in Canada with a market capitalization of CA$53.13 million.

Operations: The company's revenue segment is focused on the acquisition, exploration, and evaluation of exploration properties, generating CA$0.44 million.

Market Cap: CA$53.13M

Azimut Exploration Inc., with a market cap of CA$53.13 million, is a pre-revenue entity focused on mineral exploration in Canada. The company recently reported net income of CA$0.0426 million for the year ending August 31, 2024, marking a turnaround from the previous year's loss. Azimut's exploration efforts have yielded promising results, particularly in Quebec's Eeyou Istchee James Bay region, where significant lithium and antimony discoveries were made. These findings could enhance its strategic position amid rising demand for critical minerals. With no debt and substantial short-term assets exceeding liabilities, Azimut is financially stable to pursue further exploration initiatives.

• Dive into the specifics of Azimut Exploration here with our thorough balance sheet health report.
• Understand Azimut Exploration's track record by examining our performance history report.

Oroco Resource (TSXV:OCO)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Oroco Resource Corp. is an exploration stage company focused on acquiring and exploring mineral properties in Mexico, with a market cap of CA$70.55 million.

Operations: Oroco Resource Corp. currently does not report any revenue segments as it is in the exploration stage.

Market Cap: CA$70.55M

Oroco Resource Corp., with a market cap of CA$70.55 million, remains in the exploration stage and is pre-revenue, reporting less than US$1 million in revenue. The company has no debt but faces financial challenges with less than a year of cash runway based on current free cash flow trends. Recent earnings showed a net loss of CA$1.25 million for the first quarter ending August 31, 2024, an increase from the previous year's loss. Shareholders experienced dilution over the past year as shares outstanding grew by 9.2%. Despite these hurdles, Oroco maintains experienced management and board teams.

• Navigate through the intricacies of Oroco Resource with our comprehensive balance sheet health report here.
• Gain insights into Oroco Resource's historical outcomes by reviewing our past performance report.

Taking Advantage

• Embark on your investment journey to our 945 TSX Penny Stocks selection here.
• Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
• Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com